TA
FATE icon

TFG Advisers’s Fate Therapeutics FATE Stock Holding History

TFG Advisers’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,001
Closed -$310K – 199
2022
Q1 		$310K Sell
8,001
-263
-3% -$10.2K 0.14% 150
2021
Q4 		$484K Sell
8,264
-407
-5% -$23.1K 0.21% 119
2021
Q3 		$514K Buy
8,671
+274
+3% +$21.5K 0.25% 105
2021
Q2 		$729K Sell
8,397
-147
-2% -$11.8K 0.35% 81
2021
Q1 		$704K Sell
8,544
-74
-0.9% -$7.09K 0.36% 77
2020
Q4 		$783K Buy
8,618
+1,111
+15% +$69K 0.41% 70
2020
Q3 		$300K Buy
+7,507
New +$262K 0.17% 134
2020
Q1 		– Sell
-2,184
Closed -$42K – 244
2019
Q4 		$42K Buy
+2,184
New +$34.7K 0.02% 284

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

TFG Advisers's FATE Position: Q2 2022 in Review

TFG Advisers sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 8,001 shares — an estimated $310K sold.

TFG Advisers first reported a position in FATE in Q4 2019 and held it in 8 quarters. The position peaked at $783K in Q4 2020. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • TFG Advisers reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • TFG Advisers sold 8,001 Fate Therapeutics shares in Q2 2022, an estimated $310K.
  • TFG Advisers first reported a position in Fate Therapeutics in Q4 2019 and held it in 8 quarters.
  • TFG Advisers's Fate Therapeutics position peaked at $783K in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on TFG Advisers's 13F filing for Q2 2022, filed 20 Jul 2022.